Advertisement

Neurotherapeutics

, Volume 16, Issue 3, pp 600–610 | Cite as

Consequences of Metabolic Disruption in Alzheimer’s Disease Pathology

  • J. C. Ryu
  • E. R. Zimmer
  • P. Rosa-Neto
  • S. O. YoonEmail author
Review

Abstract

Alzheimer’s disease (AD) is an irreversible, progressive disease that slowly destroys cognitive function, such as thinking, remembering, and reasoning, to a level that one cannot carry out a daily living. As people live longer, the risk of developing AD has increased to 1 in 10 among people who are older than 65 and to almost 1 in 2 among those who are older than 85 according to a 2019 Alzheimer’s Association report. As a most common cause of dementia, AD accounts for 60–80% of all dementia cases. AD is characterized by amyloid plaques and neurofibrillary tangles, composed of extracellular aggregates of amyloid-β peptides and intracellular aggregates of hyperphosphorylated tau, respectively. Besides plaques and tangles, AD pathology includes synaptic dysfunction including loss of synapses, inflammation, brain atrophy, and brain hypometabolism, all of which contribute to progressive cognitive decline. Recent genetic studies of sporadic cases of AD have identified a score of risk factors, as reported by Hollingworth et al. (Nat Genet 43:429–435, 2001) and Lambert et al. (Nat Genet 45:1452–1458, 2013). Of all these genes, apolipoprotein E4 (APOE4) still presents the biggest risk factor for sporadic cases of AD, as stated in Saunders et al. (Neurology 43:1467–1472, 1993): depending on whether you have 1 or 2 copies of APOE4 allele, the risk increases from 3- to 12-fold, respectively, in line with Genin et al. (Mol Psychiatry 16:903–907, 2011). Besides these genetic risk factors, having type 2 diabetes (T2D), a chronic metabolic disease, is known to increase the AD risk by at least 2-fold when these individuals age, conforming to Sims-Robinson et al. (Nat Rev Neurol 6:551–559, 2010). Diabetes is reaching a pandemic scale with over 422 million people diagnosed worldwide in 2014 according to World Health Organization. Although what proportion of these diabetic patients develop AD is not known, even if 10% of diabetic patients develop AD later in their life, it would double the number of AD patients in the world. Better understanding between T2D and AD is of paramount of importance for the future. The goal of this review is to examine our current understanding on metabolic dysfunction in AD, so that a potential target can be identified in the near future.

Keywords

Alzheimer's disease Type 2 diabetes Leptin resistance Insulin resistance Circadian rhythm Brain hypometabolism 

Notes

References

  1. 1.
    Allen KV, Frier BM, Strachan MW. 2004. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490: 169–175Google Scholar
  2. 2.
    Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, et al. 2006. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 47: 867–872Google Scholar
  3. 3.
    Asher G, Gatfield D, Stratmann M, Reinke H, Dibner C, et al. 2008. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 134: 317–328Google Scholar
  4. 4.
    Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. 2011. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 68: 51–57Google Scholar
  5. 5.
    Balland E, Dam J, Langlet F, Caron E, Steculorum S, et al. 2014. Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain. Cell Metab 19: 293–301Google Scholar
  6. 6.
    Barriere DA, Noll C, Roussy G, Lizotte F, Kessai A, et al. 2018. Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. Sci Rep 8: 424Google Scholar
  7. 7.
    Bass J, Takahashi JS. 2010. Circadian integration of metabolism and energetics. Science 330: 1349–1354Google Scholar
  8. 8.
    Benford H, Bolborea M, Pollatzek E, Lossow K, Hermans-Borgmeyer I, et al. 2017. A sweet taste receptor-dependent mechanism of glucosensing in hypothalamic tanycytes. Glia 65: 773–789Google Scholar
  9. 9.
    Bigalke B, Schreitmuller B, Sopova K, Paul A, Stransky E, et al. 2011. Adipocytokines and CD34 progenitor cells in Alzheimer’s disease. PLoS One 6: e20286Google Scholar
  10. 10.
    Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. 2011. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis 26: 627–645Google Scholar
  11. 11.
    Boersma GJ, Johansson E, Pereira MJ, Heurling K, Skrtic S, et al. 2018. Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study. Horm Metab Res 50: 627–639Google Scholar
  12. 12.
    Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, et al. 2012. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest 122: 1339–1353Google Scholar
  13. 13.
    Bonda DJ, Stone JG, Torres SL, Siedlak SL, Perry G, et al. 2014. Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. J Neurochem 128: 162–172Google Scholar
  14. 14.
    Bredesen DE. 2014. Reversal of cognitive decline: a novel therapeutic program. Aging (Albany NY) 6: 707–717Google Scholar
  15. 15.
    Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, et al. 2000. Role of brain insulin receptor in control of body weight and reproduction. Science 289: 2122–2125Google Scholar
  16. 16.
    Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, et al. 2008. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science 321: 1686–1689Google Scholar
  17. 17.
    Byun K, Gil SY, Namkoong C, Youn BS, Huang H, et al. 2014. Clusterin/ApoJ enhances central leptin signaling through Lrp2-mediated endocytosis. EMBO Rep 15: 801–808Google Scholar
  18. 18.
    Canabal DD, Song Z, Potian JG, Beuve A, McArdle JJ, Routh VH. 2007. Glucose, insulin, and leptin signaling pathways modulate nitric oxide synthesis in glucose-inhibited neurons in the ventromedial hypothalamus. Am J Physiol Regul Integr Comp Physiol 292: R1418–R1428Google Scholar
  19. 19.
    Ceriani MF, Hogenesch JB, Yanovsky M, Panda S, Straume M, Kay SA. 2002. Genome-wide expression analysis in Drosophila reveals genes controlling circadian behavior. J Neurosci 22: 9305–9319Google Scholar
  20. 20.
    Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, et al. 2005. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48: 913–922Google Scholar
  21. 21.
    Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, et al. 2009. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139: 1157–1169Google Scholar
  22. 22.
    De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, et al. 2001. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22: 529–539Google Scholar
  23. 23.
    Di Spiezio A, Sandin ES, Dore R, Muller-Fielitz H, Storck SE, et al. 2018. The LepR-mediated leptin transport across brain barriers controls food reward. Mol Metab 8: 13–22Google Scholar
  24. 24.
    Diaz-Garcia CM, Mongeon R, Lahmann C, Koveal D, Zucker H, Yellen G. 2017. Neuronal Stimulation Triggers Neuronal Glycolysis and Not Lactate Uptake. Cell Metab 26: 361–374 e4Google Scholar
  25. 25.
    Drzezga A, Altomare D, Festari C, Arbizu J, Orini S, et al. 2018. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease. Eur J Nucl Med Mol Imaging 45: 1487–1496Google Scholar
  26. 26.
    Ebling FJP, Lewis JE. 2018. Tanycytes and hypothalamic control of energy metabolism. Glia 66: 1176–1184Google Scholar
  27. 27.
    Eckel-Mahan K, Sassone-Corsi P. 2013. Metabolism and the circadian clock converge. Physiol Rev 93: 107–135Google Scholar
  28. 28.
    Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. 1995. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1: 1311–1314Google Scholar
  29. 29.
    Froy O. 2007. The relationship between nutrition and circadian rhythms in mammals. Front Neuroendocrinol 28: 61–71Google Scholar
  30. 30.
    Garcia-Caceres C, Quarta C, Varela L, Gao Y, Gruber T, et al. 2016. Astrocytic Insulin Signaling Couples Brain Glucose Uptake with Nutrient Availability. Cell 166: 867–880Google Scholar
  31. 31.
    Garris DR, Williams SK, Coleman DL, Morgan CR. 1984. Glucose utilization by the mouse brain: influence of age and diabetes. Brain Res 317: 141–146Google Scholar
  32. 32.
    Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, et al. 2011. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16: 903–907Google Scholar
  33. 33.
    German JP, Thaler JP, Wisse BE, Oh IS, Sarruf DA, et al. 2011. Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology 152: 394–404Google Scholar
  34. 34.
    Goertzen AL, Bao Q, Bergeron M, Blankemeyer E, Blinder S, et al. 2012. NEMA NU 4-2008 comparison of preclinical PET imaging systems. J Nucl Med 53: 1300–1309Google Scholar
  35. 35.
    Gotz J, Ittner LM. 2008. Animal models of Alzheimer’s disease and frontotemporal dementia. Nat Rev Neurosci 9: 532–544Google Scholar
  36. 36.
    Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, et al. 2005. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem 93: 105–117Google Scholar
  37. 37.
    Guertin AD, Zhang DP, Mak KS, Alberta JA, Kim HA. 2005. Microanatomy of axon/glial signaling during Wallerian degeneration. J Neurosci 25: 3478–3487Google Scholar
  38. 38.
    Guha A, Vasconcelos M, Cai Y, Yoneda M, Hinds A, et al. 2012. Neuroepithelial body microenvironment is a niche for a distinct subset of Clara-like precursors in the developing airways. Proc Natl Acad Sci U S A 109: 12592–12597Google Scholar
  39. 39.
    Haaksma ML, Vilela LR, Marengoni A, Calderon-Larranaga A, Leoutsakos JS, et al. 2017. Comorbidity and progression of late onset Alzheimer’s disease: A systematic review. PLoS One 12: e0177044Google Scholar
  40. 40.
    Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269: 543–546Google Scholar
  41. 41.
    Hauser WA, Morris ML, Heston LL, Anderson VE. 1986. Seizures and myoclonus in patients with Alzheimer’s disease. Neurology 36: 1226–1230Google Scholar
  42. 42.
    Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. 1996. Dementia and adult-onset unprovoked seizures. Neurology 46: 727–730Google Scholar
  43. 43.
    Hileman SM, Pierroz DD, Masuzaki H, Bjorbaek C, El-Haschimi K, et al. 2002. Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 143: 775–783Google Scholar
  44. 44.
    Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, et al. 2009. Serum leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol Aging 30: 1483–1489Google Scholar
  45. 45.
    Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43: 429–435Google Scholar
  46. 46.
    Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, et al. 2019. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363: 880–884Google Scholar
  47. 47.
    Holtzman DM, Morris JC, Goate AM. 2011. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3: 77sr1Google Scholar
  48. 48.
    Ishii M, Wang G, Racchumi G, Dyke JP, Iadecola C. 2014. Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. J Neurosci 34: 9096–9106Google Scholar
  49. 49.
    Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. 2018. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14: 535–562Google Scholar
  50. 50.
    Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, et al. 2013. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12: 207–216Google Scholar
  51. 51.
    Johnston JM, Hu WT, Fardo DW, Greco SJ, Perry G, et al. 2014. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res 11: 165–174Google Scholar
  52. 52.
    Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, et al. 2003. APP processing and synaptic function. Neuron 37: 925–937Google Scholar
  53. 53.
    Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, et al. 2009. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326: 1005–1007Google Scholar
  54. 54.
    Karlsson BH, Knutsson AK, Lindahl BO, Alfredsson LS. 2003. Metabolic disturbances in male workers with rotating three-shift work. Results of the WOLF study. Int Arch Occup Environ Health 76: 424–430Google Scholar
  55. 55.
    Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, et al. 1995. Prospective study of shift work and risk of coronary heart disease in women. Circulation 92: 3178–3182Google Scholar
  56. 56.
    Khemka VK, Bagchi D, Bandyopadhyay K, Bir A, Chattopadhyay M, et al. 2014. Altered serum levels of adipokines and insulin in probable Alzheimer’s disease. J Alzheimers Dis 41: 525–533Google Scholar
  57. 57.
    Kleinridders A. 2016. Deciphering Brain Insulin Receptor and Insulin-Like Growth Factor 1 Receptor Signalling. J Neuroendocrinol 28Google Scholar
  58. 58.
    Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, et al. 2009. Limitations of small animal PET imaging with [18F] FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer’s disease. Mol Imaging Biol 11: 236–240Google Scholar
  59. 59.
    la Fleur SE, Kalsbeek A, Wortel J, Fekkes ML, Buijs RM. 2001a. A daily rhythm in glucose tolerance: a role for the suprachiasmatic nucleus. Diabetes 50: 1237–1243Google Scholar
  60. 60.
    la Fleur SE, Kalsbeek A, Wortel J, van der Vliet J, Buijs RM. 2001b. Role for the pineal and melatonin in glucose homeostasis: pinealectomy increases night-time glucose concentrations. J Neuroendocrinol 13: 1025–1032Google Scholar
  61. 61.
    Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, et al. 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45: 1452–1458Google Scholar
  62. 62.
    Lamia KA, Sachdeva UM, DiTacchio L, Williams EC, Alvarez JG, et al. 2009. AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science 326: 437–440Google Scholar
  63. 63.
    Lancelot S, Zimmer L. 2010. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci 31: 411–417Google Scholar
  64. 64.
    Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, et al. 2010. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75: 230–238Google Scholar
  65. 65.
    Lane-Donovan C, Herz J. 2017. ApoE, ApoE Receptors, and the Synapse in Alzheimer’s Disease. Trends Endocrinol Metab 28: 273–284Google Scholar
  66. 66.
    Langmesser S, Albrecht U. 2006. Life time-circadian clocks, mitochondria and metabolism. Chronobiol Int 23: 151–157Google Scholar
  67. 67.
    Last D, Alsop DC, Abduljalil AM, Marquis RP, de Bazelaire C, et al. 2007. Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care 30: 1193–1199Google Scholar
  68. 68.
    Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, et al. 2009. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302: 2565–2572Google Scholar
  69. 69.
    Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9: 106–118Google Scholar
  70. 70.
    Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. 2011. Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol 225: 54–62Google Scholar
  71. 71.
    Lopez-Lopez C, Dietrich MO, Metzger F, Loetscher H, Torres-Aleman I. 2007. Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer’s disease. J Neurosci 27: 824–831Google Scholar
  72. 72.
    Lucey BP, Mawuenyega KG, Patterson BW, Elbert DL, Ovod V, et al. 2017. Associations Between beta-Amyloid Kinetics and the beta-Amyloid Diurnal Pattern in the Central Nervous System. JAMA Neurol 74: 207–215Google Scholar
  73. 73.
    Lundgaard I, Li B, Xie L, Kang H, Sanggaard S, et al. 2015. Direct neuronal glucose uptake heralds activity-dependent increases in cerebral metabolism. Nat Commun 6: 6807Google Scholar
  74. 74.
    Luo F, Rustay NR, Ebert U, Hradil VP, Cole TB, et al. 2012. Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer’s disease. Neurobiol Aging 33: 933–944Google Scholar
  75. 75.
    Lutz MW, Sundseth SS, Burns DK, Saunders AM, Hayden KM, et al. 2016. A Genetics-based Biomarker Risk Algorithm for Predicting Risk of Alzheimer’s Disease. Alzheimers Dement (N Y) 2: 30–44Google Scholar
  76. 76.
    Macauley SL, Stanley M, Caesar EE, Yamada SA, Raichle ME, et al. 2015. Hyperglycemia modulates extracellular amyloid-beta concentrations and neuronal activity in vivo. J Clin Invest 125: 2463–2467Google Scholar
  77. 77.
    Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F. 2013. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron 78: 94–108Google Scholar
  78. 78.
    Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, et al. 2012. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 9: 8Google Scholar
  79. 79.
    Matschinsky FM. 1990. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 39: 647–652Google Scholar
  80. 80.
    McNay EC, Recknagel AK. 2011. Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem 96: 432–442Google Scholar
  81. 81.
    Mendez M, Lim G. 2003. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 20: 791–803Google Scholar
  82. 82.
    Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, et al. 2004. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428: 569–574Google Scholar
  83. 83.
    Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. 1997. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42: 85–94Google Scholar
  84. 84.
    Mosconi L. 2005. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32: 486–510Google Scholar
  85. 85.
    Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. 2007. Early detection of Alzheimer’s disease using neuroimaging. Exp Gerontol 42: 129–138Google Scholar
  86. 86.
    Mosconi L, De Santi S, Li Y, Li J, Zhan J, et al. 2006. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET. Eur J Nucl Med Mol Imaging 33: 210–221Google Scholar
  87. 87.
    Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, et al. 2008. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 134: 329–340Google Scholar
  88. 88.
    Nestor PJ, Fryer TD, Smielewski P, Hodges JR. 2003. Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol 54: 343–351Google Scholar
  89. 89.
    Oosterman JE, Kalsbeek A, la Fleur SE, Belsham DD. 2015. Impact of nutrients on circadian rhythmicity. Am J Physiol Regul Integr Comp Physiol 308: R337–R350Google Scholar
  90. 90.
    Palop JJ, Mucke L. 2009. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66: 435–440Google Scholar
  91. 91.
    Panda S, Antoch MP, Miller BH, Su AI, Schook AB, et al. 2002. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109: 307–320Google Scholar
  92. 92.
    Parent MJ, Zimmer ER, Shin M, Kang MS, Fonov VS, et al. 2017. Multimodal Imaging in Rat Model Recapitulates Alzheimer’s Disease Biomarkers Abnormalities. J Neurosci 37: 12263–12271Google Scholar
  93. 93.
    Parkes KR. 2002. Shift work and age as interactive predictors of body mass index among offshore workers. Scand J Work Environ Health 28: 64–71Google Scholar
  94. 94.
    Pei JJ, Khatoon S, An WL, Nordlinder M, Tanaka T, et al. 2003. Role of protein kinase B in Alzheimer’s neurofibrillary pathology. Acta Neuropathol 105: 381–392Google Scholar
  95. 95.
    Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging S. 2002. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51: 1256–1262Google Scholar
  96. 96.
    Placais PY, de Tredern E, Scheunemann L, Trannoy S, Goguel V, et al. 2017. Upregulated energy metabolism in the Drosophila mushroom body is the trigger for long-term memory. Nat Commun 8: 15510Google Scholar
  97. 97.
    Power DA, Noel J, Collins R, O'Neill D. 2001. Circulating leptin levels and weight loss in Alzheimer’s disease patients. Dement Geriatr Cogn Disord 12: 167–170Google Scholar
  98. 98.
    Prinz PN, Peskind ER, Vitaliano PP, Raskind MA, Eisdorfer C, et al. 1982a. Changes in the sleep and waking EEGs of nondemented and demented elderly subjects. J Am Geriatr Soc 30: 86–93Google Scholar
  99. 99.
    Prinz PN, Vitaliano PP, Vitiello MV, Bokan J, Raskind M, et al. 1982b. Sleep, EEG and mental function changes in senile dementia of the Alzheimer’s type. Neurobiol Aging 3: 361–370Google Scholar
  100. 100.
    Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, et al. 2008. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 64: 388–401Google Scholar
  101. 101.
    Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, et al. 2011. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77: 2034–2042Google Scholar
  102. 102.
    Raikwar SP, Bhagavan SM, Ramaswamy SB, Thangavel R, Dubova I, et al. 2018. Are Tanycytes the Missing Link Between Type 2 Diabetes and Alzheimer’s Disease? Mol Neurobiol Google Scholar
  103. 103.
    Rapic S, Backes H, Viel T, Kummer MP, Monfared P, et al. 2013. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer’s disease. Neurobiol Aging 34: 351–354Google Scholar
  104. 104.
    Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, et al. 1996. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334: 752–758Google Scholar
  105. 105.
    Robins SC, Stewart I, McNay DE, Taylor V, Giachino C, et al. 2013. alpha-Tanycytes of the adult hypothalamic third ventricle include distinct populations of FGF-responsive neural progenitors. Nat Commun 4: 2049Google Scholar
  106. 106.
    Rodriguez EM, Blazquez JL, Pastor FE, Pelaez B, Pena P, et al. 2005. Hypothalamic tanycytes: a key component of brain-endocrine interaction. Int Rev Cytol 247: 89–164Google Scholar
  107. 107.
    Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, et al. 2012. Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer’s disease pathology. Sci Transl Med 4: 150ra22Google Scholar
  108. 108.
    Romanelli MF, Morris JC, Ashkin K, Coben LA. 1990. Advanced Alzheimer’s disease is a risk factor for late-onset seizures. Arch Neurol 47: 847–850Google Scholar
  109. 109.
    Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, et al. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43: 1467–1472Google Scholar
  110. 110.
    Scarmeas N, Honig LS, Choi H, Cantero J, Brandt J, et al. 2009. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 66: 992–997Google Scholar
  111. 111.
    Scholl M, Damian A, Engler H. 2014. Fluorodeoxyglucose PET in Neurology and Psychiatry. PET Clin 9: 371–390, vGoogle Scholar
  112. 112.
    Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, et al. 1996. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci 777: 57–64Google Scholar
  113. 113.
    Shibata M, Yasuda B. 1980. New experimental congenital diabetic mice (N.S.Y. mice). Tohoku J Exp Med 130: 139–142Google Scholar
  114. 114.
    Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, et al. 2001. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286: 2120–2127Google Scholar
  115. 115.
    Silverman DH, Small GW, Phelps ME. 1999. Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer’s Disease. Clin Positron Imaging 2: 119–130Google Scholar
  116. 116.
    Sims-Robinson C, Kim B, Rosko A, Feldman EL. 2010. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6: 551–559Google Scholar
  117. 117.
    Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, et al. 2009. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66: 638–645Google Scholar
  118. 118.
    Son SM, Jung ES, Shin HJ, Byun J, Mook-Jung I. 2012. Abeta-induced formation of autophagosomes is mediated by RAGE-CaMKKbeta-AMPK signaling. Neurobiol Aging 33: 1006 e11–e23Google Scholar
  119. 119.
    Song H, Moon M, Choe HK, Han DH, Jang C, et al. 2015. Abeta-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer’s disease. Mol Neurodegener 10: 13Google Scholar
  120. 120.
    Stanley M, Macauley SL, Holtzman DM. 2016. Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence? J Exp Med 213: 1375–1385Google Scholar
  121. 121.
    Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. 2005. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes? J Alzheimers Dis 7: 63–80Google Scholar
  122. 122.
    Steinbusch L, Labouebe G, Thorens B. 2015. Brain glucose sensing in homeostatic and hedonic regulation. Trends Endocrinol Metab 26: 455–466Google Scholar
  123. 123.
    Sterniczuk R, Dyck RH, Laferla FM, Antle MC. 2010. Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: part 1. Circadian changes. Brain Res 1348: 139–148Google Scholar
  124. 124.
    Stohr O, Schilbach K, Moll L, Hettich MM, Freude S, et al. 2013. Insulin receptor signaling mediates APP processing and beta-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer’s disease. Age (Dordr) 35: 83–101Google Scholar
  125. 125.
    Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, et al. 2010. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107: 7036–7041Google Scholar
  126. 126.
    Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, et al. 2012. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122: 1316–1338Google Scholar
  127. 127.
    Terauchi Y, Sakura H, Yasuda K, Iwamoto K, Takahashi N, et al. 1995. Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J. Biol. Chem. 270: 30253–30256Google Scholar
  128. 128.
    Thornton C, Bright NJ, Sastre M, Muckett PJ, Carling D. 2011. AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem J 434: 503–512Google Scholar
  129. 129.
    Unger JW, Livingston JN, Moss AM. 1991a. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 36: 343–362Google Scholar
  130. 130.
    Unger JW, Moss AM, Livingston JN. 1991b. Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat. Neuroscience 42: 853–861Google Scholar
  131. 131.
    van Amelsvoort LG, Schouten EG, Kok FJ. 1999. Duration of shiftwork related to body mass index and waist to hip ratio. Int J Obes Relat Metab Disord 23: 973–978Google Scholar
  132. 132.
    Vandal M, White PJ, Chevrier G, Tremblay C, St-Amour I, et al. 2015. Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer’s disease. FASEB J 29: 4273–4284Google Scholar
  133. 133.
    Vannucci SJ, Gibbs EM, Simpson IA. 1997. Glucose utilization and glucose transporter proteins GLUT-1 and GLUT-3 in brains of diabetic (db/db) mice. Am J Physiol 272: E267–E274Google Scholar
  134. 134.
    Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, et al. 2015. Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. JAMA Neurol 72: 1013–1020Google Scholar
  135. 135.
    Williams T, Courchet J, Viollet B, Brenman JE, Polleux F. 2011. AMP-activated protein kinase (AMPK) activity is not required for neuronal development but regulates axogenesis during metabolic stress. Proc Natl Acad Sci U S A 108: 5849–5854Google Scholar
  136. 136.
    Wyss MT, Jolivet R, Buck A, Magistretti PJ, Weber B. 2011. In vivo evidence for lactate as a neuronal energy source. J Neurosci 31: 7477–7485Google Scholar
  137. 137.
    Xie L, Kang H, Xu Q, Chen MJ, Liao Y, et al. 2013. Sleep drives metabolite clearance from the adult brain. Science 342: 373–377Google Scholar
  138. 138.
    Yamamoto K, Tanei ZI, Hashimoto T, Wakabayashi T, Okuno H, et al. 2015. Chronic optogenetic activation augments abeta pathology in a mouse model of Alzheimer disease. Cell Rep 11: 859–865Google Scholar
  139. 139.
    Yarchoan M, Toledo JB, Lee EB, Arvanitakis Z, Kazi H, et al. 2014. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Neuropathol 128: 679–689Google Scholar
  140. 140.
    Yi D, Lee DY, Sohn BK, Choe YM, Seo EH, et al. 2014. Beta-amyloid associated differential effects of APOE epsilon4 on brain metabolism in cognitively normal elderly. Am J Geriatr Psychiatry 22: 961–970Google Scholar
  141. 141.
    Yin H, Tian S, Huang R, Cai R, Guo D, et al. 2018. Low Plasma Leptin and High Soluble Leptin Receptor Levels Are Associated With Mild Cognitive Impairment in Type 2 Diabetic Patients. Front Aging Neurosci 10: 132Google Scholar
  142. 142.
    Yoon So, Park, D.J., Ryu, J.C., Ozer, H.G., Tep, C., Shin, Y.J., Lim, T.H., Pastorino, L., Kunwar, A.J., Walton, J.C., Nagahara, A.H., Lu, K.P., Nelson, R.J., Tuszynski, M.H., Huan, K. 2012. JNK3 perpetuates metabolic stress induced by Abeta peptides. Neuron 75: 824Google Scholar
  143. 143.
    Yuan SM, Gao K, Wang DM, Quan XZ, Liu JN, et al. 2011. Evodiamine improves congnitive abilities in SAMP8 and APP (swe)/PS1(DeltaE9) transgenic mouse models of Alzheimer’s disease. Acta Pharmacol Sin 32: 295–302Google Scholar
  144. 144.
    Zhao N, Liu CC, Van Ingelgom AJ, Martens YA, Linares C, et al. 2017. Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. Neuron 96: 115–129 e5Google Scholar
  145. 145.
    Zhou L, Gao Q, Nie M, Gu JL, Hao W, et al. 2016. Degeneration and energy shortage in the suprachiasmatic nucleus underlies the circadian rhythm disturbance in ApoE(-/-) mice: implications for Alzheimer’s disease. Sci Rep 6: 36335Google Scholar
  146. 146.
    Zimmer ER, Parent MJ, Cuello AC, Gauthier S, Rosa-Neto P. 2014. MicroPET imaging and transgenic models: a blueprint for Alzheimer’s disease clinical research. Trends Neurosci 37: 629–641Google Scholar
  147. 147.
    Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, et al. 2017. [(18)F] FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci 20: 393–395Google Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2019

Authors and Affiliations

  • J. C. Ryu
    • 1
  • E. R. Zimmer
    • 2
    • 3
    • 4
    • 5
  • P. Rosa-Neto
    • 6
  • S. O. Yoon
    • 1
    Email author
  1. 1.Department of Biological Chemistry & PharmacologyOhio State UniversityColumbusUSA
  2. 2.Department of PharmacologyUFRGSPorto AlegreBrazil
  3. 3.Graduate Program in Biological Sciences: BiochemistryUniversidade Federal do Rio Grande do Sul (UFRGS)Porto AlegreBrazil
  4. 4.Graduate Program in Biological Sciences: Pharmacology and TherapeuticsUFRGSPorto AlegreBrazil
  5. 5.Brain Institute of Rio Grande do Sul (BraIns)Pontifical Catholic University of Rio Grande do SulPorto AlegreBrazil
  6. 6.Montreal Neurological InstituteMontrealCanada

Personalised recommendations